Replies to post #145896 on Biotech Values

[masterlongevity]

dissappointing for patients. there must not have been a hint of efficacy if they also dropped the patients out of the extension study

[DewDiligence]

PFE’s Bapineuzumab PR is highly irregular insofar as PFE alone is reporting on a conducted by JNJ—despite the fact that JNJ said no information would be released on either of the two JNJ trials (301 and 302) until the full datasets from both trials were presented at a medical conference.

Give PFE credit for not being a party to a cover-up. I’ll bet JNJ’s lawyers threatened PFE with breach of contract for speaking out of turn, and PFE told them to go fly a kite.